Fundraising Fox
Rivermark
Milwaukee, US · Founded 2021 · 2 known investors
Find your way into Rivermark
Sign up to see every warm intro you have to Rivermark
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rivermark team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Rivermark Medical develops FloStent, a first-line device for treating benign prostatic hyperplasia (BPH) that is delivered during routine outpatient cystoscopy for urology practices and their patients. The device aims to restore urinary flow while preserving future treatment options.
Founders & leadership
AD
Anand DoraiswamyExecutive
AK
Adam KadlecPresident & CEOCo-founder and CEO of Rivermark Medical, which develops FloStent, a device for treating benign prostatic hyperplasia delivered during routine outpatient cystoscopy.
Board
SB
Scott ButtonBoard director
CM
ME
Matthew ErcolaniBoard director
JB
Josh BaltzellBoard director
JB
Joseph BillerBoard director
Investors · 2
Andera Partnerslisted by Andera PartnersParis
How we know: Andera Partners's portfolio page · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$35.9M disclosed across 3 rounds · 2021–2024
▶$30MraisedOct 2024 · 16 investors · Other TechnologyRule 506(b)
▶$30MraisedOct 2024 · 16 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Josh BaltzellDirector
- Carter MeyerDirector
- Matthew ErcolaniDirector
- Anand DoraiswamyExecutive Officer, Director
- Scott ButtonDirector
- Adam KadlecExecutive Officer, Director
- Joseph BillerDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$4.1MraisedOct 2024 · 6 investors · Other TechnologyRule 506(b)
▶$4.1MraisedOct 2024 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Anand DoraiswamyExecutive Officer, Director
- Adam KadlecExecutive Officer, Director
- Scott ButtonDirector
- Carter MeyerDirector
- Matthew ErcolaniDirector
- Josh BaltzellDirector
- Joseph BillerDirector
- Offering amount
- $4.1M
- Amount sold
- $4.1M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.8MraisedNov 2021 · 5 investors · Other TechnologyRule 506(b)
▶$1.8MraisedNov 2021 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Adam KadlecExecutive Officer, Director
- Carter MeyerDirector
- Anand DoraiswamyExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Rivermark do?
- Rivermark Medical develops FloStent, a first-line device for treating benign prostatic hyperplasia (BPH) that is delivered during routine outpatient cystoscopy for urology practices and their patients. The device aims to restore urinary flow while preserving future treatment options.
- Who are Rivermark's investors?
- Rivermark's investors include Andera Partners, View Ventures.
- How much funding has Rivermark raised?
- Rivermark has disclosed $35.9M raised across 3 rounds.
- Where is Rivermark headquartered?
- Rivermark is headquartered in Milwaukee, US.